Cure My Disease

Don't miss your cure!

 Log in / Sign up

New supplement aims to clear menopause brain fog

NCT ID NCT06748989

Symptom relief Sponsor: FEMPHARMA Kft. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This study tests a dietary supplement called Cortexium, which contains PQQ, GABA, caffeine, and B vitamins, to see if it improves memory and focus in healthy postmenopausal women. About 70 women will take either the supplement or a placebo for a period, and their cognitive function will be measured using computer tests. The goal is to find a safe, non-drug way to support brain health during menopause.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cortexium dietary supplement (pyrroloquinoline quinone, gamma-aminobutyric acid, caffeine, B vitamins)
What this could lead to
If it works, this supplement could help ease memory lapses and concentration problems that many women experience during menopause.
What could go wrong
This is a small early-stage study with only 70 participants. The supplement may not work better than a placebo, and results may not apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

70 people

The number who actually took part.

Started

May 2025

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Good general health. * Education level at least completed elementary. * Menopausal status with minimum 1 year from the last menstrual period and based on the criterion of follicle-stimulating hormone (FSH) level (FSH \> 30 mlU/ml) or a history of bilateral oophorectomy. Exclusion Criteria: * Active cancerous disease within the period of 5 years before recruitment. * Mental diseases in medical history, including depression. * Addiction to drugs and alcohol. * Symptoms of dementia or history of neurological treatment or neurocognitive disorder.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive function and memory are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive function and memory

Contacts and locations

Locations

  • Dr. Secret Private Clinic

    Debrecen, HB, 4032, Hungary